HBIO Stock Overview
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally.
Harvard Bioscience Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.58|
|52 Week High||US$8.23|
|52 Week Low||US$2.56|
|1 Month Change||-21.58%|
|3 Month Change||-31.57%|
|1 Year Change||-66.41%|
|3 Year Change||-14.29%|
|5 Year Change||-31.20%|
|Change since IPO||-75.43%|
Recent News & Updates
Harvard Bioscience GAAP EPS of $0.05 beats by $0.06, revenue of $29.2M misses by $1.2M
Harvard Bioscience press release (NASDAQ:HBIO): Q2 GAAP EPS of $0.05 beats by $0.06. Revenue of $29.2M (flat Y/Y) misses by $1.2M. “Looking at the full year 2022, considering significant currency impacts, volatility in Europe and continued Covid related impacts in China, we are taking a more conservative view on revenue and expect 1-to-5% reported revenue growth and adjusted operating margin for the year of 13-to-14%.” said Jim Green, Chairman and CEO
|HBIO||US Life Sciences||US Market|
Return vs Industry: HBIO underperformed the US Life Sciences industry which returned -35.1% over the past year.
Return vs Market: HBIO underperformed the US Market which returned -23% over the past year.
|HBIO Average Weekly Movement||5.4%|
|Life Sciences Industry Average Movement||9.7%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.8%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: HBIO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: HBIO's weekly volatility (5%) has been stable over the past year.
About the Company
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products.
Harvard Bioscience Fundamentals Summary
|HBIO fundamental statistics|
Is HBIO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|HBIO income statement (TTM)|
|Cost of Revenue||US$52.02m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.088|
|Net Profit Margin||-3.03%|
How did HBIO perform over the long term?See historical performance and comparison
Is HBIO undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for HBIO?
Other financial metrics that can be useful for relative valuation.
|What is HBIO's n/a Ratio?|
Price to Sales Ratio vs Peers
How does HBIO's PS Ratio compare to its peers?
|HBIO PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
TKNO Alpha Teknova
LAB Standard BioTools
RPID Rapid Micro Biosystems
HBIO Harvard Bioscience
Price-To-Sales vs Peers: HBIO is good value based on its Price-To-Sales Ratio (0.9x) compared to the peer average (3.5x).
Price to Earnings Ratio vs Industry
How does HBIO's PE Ratio compare vs other companies in the US Life Sciences Industry?
Price-To-Sales vs Industry: HBIO is good value based on its Price-To-Sales Ratio (0.9x) compared to the US Life Sciences industry average (3.7x)
Price to Sales Ratio vs Fair Ratio
What is HBIO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||0.9x|
|Fair PS Ratio||2.1x|
Price-To-Sales vs Fair Ratio: HBIO is good value based on its Price-To-Sales Ratio (0.9x) compared to the estimated Fair Price-To-Sales Ratio (2.1x).
Share Price vs Fair Value
What is the Fair Price of HBIO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: HBIO ($2.58) is trading below our estimate of fair value ($11.87)
Significantly Below Fair Value: HBIO is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
How is Harvard Bioscience forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HBIO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: HBIO is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: HBIO is expected to become profitable in the next 3 years.
Revenue vs Market: HBIO's revenue (9.8% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: HBIO's revenue (9.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HBIO's Return on Equity is forecast to be low in 3 years time (7.8%).
Discover growth companies
How has Harvard Bioscience performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HBIO is currently unprofitable.
Growing Profit Margin: HBIO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: HBIO is unprofitable, but has reduced losses over the past 5 years at a rate of 2.9% per year.
Accelerating Growth: Unable to compare HBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HBIO is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (15.6%).
Return on Equity
High ROE: HBIO has a negative Return on Equity (-4.71%), as it is currently unprofitable.
Discover strong past performing companies
How is Harvard Bioscience's financial position?
Financial Health Score2/6
Financial Health Score 2/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: HBIO's short term assets ($56.5M) exceed its short term liabilities ($23.4M).
Long Term Liabilities: HBIO's short term assets ($56.5M) exceed its long term liabilities ($54.4M).
Debt to Equity History and Analysis
Debt Level: HBIO's net debt to equity ratio (57.1%) is considered high.
Reducing Debt: HBIO's debt to equity ratio has increased from 17.6% to 62.6% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HBIO has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if HBIO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
What is Harvard Bioscience current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HBIO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HBIO's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as HBIO has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jim Green (64 yo)
Mr. James W. Green, also known as Jim, has been the Chairman of Harvard Bioscience, Inc. since June 5, 2017 and its Director since April 30, 2015. He serves as President and Chief Executive Officer of Harv...
CEO Compensation Analysis
Compensation vs Market: Jim's total compensation ($USD2.74M) is above average for companies of similar size in the US market ($USD780.01K).
Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.
Experienced Management: HBIO's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.
Experienced Board: HBIO's board of directors are considered experienced (4.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: HBIO insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|26 Aug 22||BuyUS$31,682||Bertrand Loy||Individual||9,291||US$3.41|
|25 Aug 22||BuyUS$83,385||Bertrand Loy||Individual||25,535||US$3.34|
|23 Aug 22||BuyUS$44,414||Bertrand Loy||Individual||13,857||US$3.23|
|19 Aug 22||BuyUS$35,186||Bertrand Loy||Individual||10,759||US$3.28|
|17 Aug 22||BuyUS$127,600||James Green||Individual||40,000||US$3.19|
|15 Jun 22||BuyUS$111,300||James Green||Individual||30,000||US$3.71|
|09 May 22||BuyUS$147,400||James Green||Individual||40,000||US$3.78|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.1%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Harvard Bioscience, Inc.'s employee growth, exchange listings and data sources
- Name: Harvard Bioscience, Inc.
- Ticker: HBIO
- Exchange: NasdaqGM
- Founded: 1901
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$107.422m
- Shares outstanding: 41.64m
- Website: https://www.harvardbioscience.com
Number of Employees
- Harvard Bioscience, Inc.
- 84 October Hill Road
- Suite 10
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|HBIO||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Dec 2000|
|HBI||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Dec 2000|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/25 00:00|
|End of Day Share Price||2022/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.